Materials UDP-GlcNAc and CTD110.6 antibody were purchased from Sigma Aldrich. Immunoblotting reagents were purchased from Life Technologies. Human ProtoArray protein microarrays were purchased from Life Technologies. Anti-mouse IgG, Alexa-Fluor 646 conjugate was purchased from Cell Signaling. Human cDNA clones were obtained from the National Institutes of Health (NIH) mammalian gene collection (MGC). Rabbit reticulocyte lysate IVT system (TnT SP6) was purchased from Promega. 35 S-Methionine was purchased from Perkin Elmer. Azadibenzocyclooctye-5kDa-PEG (ADIBO-PEG) was purchased from Alfa Aesar. All materials for imaging of radioactive gels were purchased from GE. D283 Med cells were obtained from ATCC. All cell culture reagents were purchased from Gibco. PUGNAC and Thiamet-G were purchased from Sigma Aldrich and Complete Protease inhibitor was purchased from Roche. Galt labeling kit and all Immunoblotting materials were purchased from Life Technologies.
Microarray incubation
Human ProtoArray microarrays were washed three times (10 min each) with TBS containing 0.05% Tween 20 (TBS-T) in a plastic box containing 20 mL buffer (gently tilted). Microarrays were then blocked for 1 h at 4 °C with Microarray Blocking solution (ArrayIt). Microarrays were incubated with purified ncOGT [3µM] or mOGT [3µM] and 40µM UDP-GlcNAc under a coverslip for 1 h at 25°C. The arrays were then washed as above with the addition of a wash (middle wash) with 0.5% SDS. Microarrays were incubated with primary antibody (O-GlcNAc, CTD1110.6; 1:250 dilution) overnight. To label modified proteins, an anti-mouse Alexa Fluor® 647-conjugated secondary antibody (1:250 dilution) was incubated for 1 h at RT. The arrays were washed again, spin-dried (200 × g, 5 min), and scanned.
Images and Data Processing
Results were recorded as TIFF files and Images were quantified using GenePix Pro 5 feature extraction software (version 4000B). Scanning parameters were set so that none of the spots showed saturation: PMT gain value = 400 and laser power = 30%. For each spot, the local background intensity was subtracted from the median spot intensity. The data set was organized in a matrix where each column contains the reactivities measured for a given array and each row contains the reactivities measured for a given protein over all arrays. The negative values were set to zero and the data were then normalized using the quantile normalization algorithm 2 . The signal intensity for each spot on a control array (not incubated with exogenous OGT) was subtracted from the corresponding spot of the arrays incubated with ncOGT and mOGT. The Top 2% of signal intensities after this subtraction were considered positive targets of OGT (Table S1 and S2). Each OGT isoform (ncOGT and mOGT) gave 159 proteins as the top 2% of hits for a total of 318 proteins. 88 of those proteins are shared between the isoforms so we report 230 unique OGT substrates. Because only one array was incubated for each isoform, we cannot draw any conclusions about how differences in TPR length affect substrate selection.
In vitro validation of OGT Targets
Coupled in vitro transcription and translation was performed on selected human cDNA clones using a rabbit reticulocyte lysate system. Resulting protein products were radiolabeled with 35 S -labeled methionine according to the manufacturer's instructions. Following the transcription / translation of the cDNA clone (typically 60 min), ncOGT or mOGT [2µM] and UDP-GlcNAz [100µM] were added to the reaction mixture and incubated at 37°C for 1 hour. Subsequently, Azadibenzocyclooctye-5kDa-PEG (ADIBO-PEG) was added to the reaction mixture at a final concentration of 2mM and the mixture was incubated at 25°C for 90 minutes. Following this incubation, SDS loading buffer was added to the reaction, which was then subjected to SDS-PAGE. The gel was dried and exposed to a Phosphorimager screen overnight and imaged with a Typhoon scanner.
In vivo validation of OTX2 glycosylation
D283 Med Cells were grown in F12-K media supplemented with 10%FBS and antibiotics at 37°C in a 5% CO 2 incubator. Cells were separated from the growth media by centrifugation. The cell pellet was washed in ice cold 1X PBS and then lysed in boiling 1% SDS / 20mM HEPES 7.9. After cooling to room temperature, 1mM PMSF, 10µM PUGNAC, 10µM TMG and 1X protease inhibitor were added to the solution. The mixture was sonicated and then subjected to a 5 minute incubation at 95°C. The samples were centrifuged for 15 minutes at 20K g and the supernatant was collected and it's concentration measured by BCA assay (BIO-RAD). GalT labeling of cell lysates was performed according to the manufacturer's instructions. After the Galt labeling reaction, Azadibenzocyclooctyne-5kDa-PEG (ADIBO-PEG) was added to a final concentration of 3mM and incubated at 25°C for 2 hours. The reaction was MeOH / CHCl 3 precipitated and resuspended in 1% SDS / 20mM HEPES 7.9 and SDS loading buffer. The sample was subjected to SDS-PAGE, transferred to a nitrocellulose membrane and probed with the indicated antibody. For results shown in Figure 3b , D283 Med Cells were grown in F12-K media supplemented with 10%FBS and antibiotics as described above. Upon reaching 70% confluence, cells were treated with Ac-5S-GlcNAc or DMSO at 50µM for 24 hours. After treatment, cells were separated from the growth media by centrifugation. The cell pellet was washed in ice cold 1X PBS and then lysed in boiling 1% SDS / 20mM HEPES 7.9. After cooling to room temperature, 1mM PMSF, 10µM PUGNAC, 10µM TMG and
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1X protease inhibitor were added to the solution. The mixture was sonicated and then subjected to a 5 minute incubation at 95°C. The samples were centrifuged for 15 minutes at 20K g and the supernatant was collected and it's concentration measured by BCA assay (BIO-RAD). SDS loading buffer was added to the cell lysates and the sample was subjected to SDS-PAGE, transferred to a nitrocellulose membrane and probed with the indicated antibody.
Supplementary Figures

Figure S1
Testing OGT isoforms for catalytic activity against a HeLa cell extract. Untreated HeLa cell extract (left lane) was incubated with 3µM ncOGT (2 nd lane), mOGT (3 rd lane) or sOGT (right lane) and 40µM UDP-GlcNAc for 1Hr. at 37°C. The reaction volume (typically 10µL) was then subjected to SDS-PAGE and probed for the O-GlcNAc modification using the CTD110.6 antibody (Sigma). The results show that ncOGT and mOGT are able to catalyze the addition of GlcNAc residues to protein substrates present in the HeLa cell extract, increasing the overall signal intensity from the O-GlcNAc antibody. sOGT, on the other hand, while effectively able to auto-glycosylate (arrow highlighting sOGT auto-glycosylation), does not appear to glycosylate any of the other proteins present in the extract (compare lane 1 to lane 4).
Figure S2
OGT can effectively utilize UDP-GlcNAz as a substrate. cDNA clone corresponding to Nucleoporin62 was in vitro transcribed / translated as described in methods, resulting in a strong product band (leftmost lane, each). (a) Incubating the reaction with only UDP-GlcNAc does not change the molecular weight of the Nup62 product. Adding UDP-GlcNAc and either ncOGT or mOGT results in glycosylation of the Nup62 protein product and a significant shift in molecular weight. (b) Incubating the reaction with only UDP-GlcNAz does not change the molecular weight of the Nup62 product. Adding UDP-GlcNAz and either ncOGT or mOGT results in glycosylation of the Nup62 protein product and a significant shift in molecular weight. These results indicate that OGT is able to utilize UDP-GlcNAz as a substrate in our IVT method for validating OGT targets.
Figure S3
Testing the in vitro OGT target validation method on previously known OGT substrates. cDNA clones corresponding to Nucleoporin62 (Nup62, left) and CREB regulated transcription coactivator 2 (CRTC2, right) were in vitro transcribed / translated as described in methods, resulting in a strong product band (leftmost lane, each). Incubating the reaction with only UDP-GlcNAz results in a slight mass-shift (more apparent in the Nup62 sample) that is due to the endogenous OGT present in the IVT mix. Incubating with UDP-GlcNAz and either ncOGT or mOGT results in a very robust molecular weight shift of both protein products, indicating their OGT-dependent glycosylation. All lanes in the above were treated with Azadibenzocyclooctyne-5kDa-PEG.
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Figure S4
Testing newly identified OGT substrates using the in vitro OGT target validation method. cDNA clones corresponding to OTX2, HGS, NR3C1, E2F8, C20ORF112, BAIAP2, EPB49, SSBP3, MAPK1IP1L, MEF2D, SSBP2 and MEF2A were in vitro transcribed / translated as described in methods, resulting in a strong product band (leftmost lane, each). For some protein products, incubating the reaction with only UDP-GlcNAz results in a slight mass-shift (MEF2D, MEF2A) that is due to the endogenous OGT present in the IVT mix. Incubating with UDP-GlcNAz and either ncOGT or mOGT results in a very robust molecular weight shift of all protein products, indicating their OGT-dependent glycosylation. Some protein products show a single 5kDa shift, consistent with a single glycosylation event (HGS, NR3C1, C20ORF112). All lanes in the above were treated with Azadibenzocyclooctyne-5kDa-PEG.
